Clinical Challenges: Gene Therapy for Inherited Retinal Diseases
The FDA approval of UF's AAV technology in voretigene neparvovec (Luxturna) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy almost 4 years ago marked a turning point in gene therapy.
After Nerve-Wracking Eye Surgery, the World Comes into Focus for Early Gene Therapy Recipient (STAT)
(This is a story about the first recipient of Luxturna, which is the first gene therapy for a genetic disorder approved by... Read More
